STOCK TITAN

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) will participate in a fireside chat at The Citizens JMP Life Sciences Conference in New York to discuss current oncology and autoimmune disease strategies and progress. The webcast of the chat will be available on the company's website.

Positive
  • None.
Negative
  • None.

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024.

During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress.

Presentation Details

The Citizens JMP Life Sciences Conference
Date and Time: Tuesday, May 14 2024, 12:00 – 12:25 p.m. ET
Webcast Link: https://wsw.com/webcast/jmp63/cue/1530576
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma

A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on Twitter and LinkedIn.

Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com


FAQ

When and where will Cue Biopharma participate in a fireside chat?

Cue Biopharma will participate in a fireside chat at The Citizens JMP Life Sciences Conference in New York on May 13-14, 2024.

What will Cue Biopharma discuss during the fireside chat?

Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress during the fireside chat.

Who will be the presenter at the fireside chat?

Daniel Passeri, the chief executive officer of Cue Biopharma, will be the presenter at the fireside chat.

Where can I access the live and archived webcast of the fireside chat?

The live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of Cue Biopharma's website at www.cuebiopharma.com for 30 days.

Cue Biopharma, Inc.

NASDAQ:CUE

CUE Rankings

CUE Latest News

CUE Stock Data

78.80M
45.38M
2.97%
32.9%
8.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BOSTON

About CUE

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci